Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo...

Area of Science:

• Pharmacology
• Pediatric Medicine
• Pharmacokinetics

Background:

• Aminoglycoside dosing in pediatrics is shifting towards once-daily regimens.
• Limited studies exist on optimizing gentamicin doses specifically for pediatric populations.
• This research addresses the need for evidence-based dosing strategies in pediatric gentamicin therapy.

Purpose of the Study:

• To develop a population pharmacokinetic model for gentamicin in pediatric patients.
• To utilize the model for designing optimal once-daily gentamicin dosing regimens.
• To evaluate the probability of achieving therapeutic targets and maintaining safety profiles.

Main Methods:

• Retrospective chart review of pediatric patients' gentamicin plasma concentrations (peak/trough).
• Development of a two-compartment pharmacokinetic model with weight as a covariate.
• Monte Carlo simulations to assess target attainment (Cmax/MIC ≥ 10 mg/L) across various MICs (0.5-2 mg/L) and dosing regimens.

Main Results:

• A two-compartment model with additive residual error best described gentamicin pharmacokinetics.
• Weight was a significant covariate for clearance and volume of distribution.
• Simulations showed good probability of target attainment even at MIC of 2 mg/L, with specific doses for neonates (6-7 mg/kg/day) and older children (4-5 mg/kg/day).
• Trough concentrations remained below the toxicity limit of 1 mg/L.

Conclusions:

• Once-daily gentamicin dosing is a viable strategy in pediatrics.
• This dosing approach facilitates achievement of therapeutic targets.
• It effectively maintains trough gentamicin levels below toxicity thresholds.